Mycophenolate Mofetil Teva

Mycophenolate Mofetil, the active ingredient in Mycophenolate Mofetil Teva, is an antimetabolite immunosuppressant presented as an oral dosage form for oral use. It is used to prevent organ transplant rejection and to treat lupus nephritis in appropriate patients.

GNH USA supplies Mycophenolate Mofetil Teva as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil is an antimetabolite immunosuppressant that acts on the adaptive immune response to reduce lymphocyte proliferation.

- Organ transplant rejection: helps prevent acute and chronic rejection after solid‑organ transplantation. - Lupus nephritis: reduces renal inflammation and proteinuria in patients with systemic lupus erythematosus affecting the kidneys. - Maintenance therapy after transplantation: supports long‑term graft survival by sustaining immunosuppression.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools often occurring early in therapy. - Vomiting: occasional episodes, especially with rapid dose escalation. - Abdominal pain: cramping or discomfort in the stomach area. - Headache: transient mild to moderate pain. - Tremor: fine shaking of hands or limbs.

Serious or Rare Side Effects: - Leukopenia or neutropenia: significant reduction in white blood cells. - Anemia: decreased red blood cell count leading to fatigue. - Severe infections: opportunistic bacterial, viral, or fungal infections. - Hepatotoxicity: elevated liver enzymes or liver injury. - Malignancies: increased risk of post‑transplant lymphoproliferative disorder. - Severe allergic reactions: rash, angioedema, or anaphylaxis.

Patients receiving Mycophenolate Mofetil should be monitored closely for safety concerns.

- Blood counts: monitor complete blood count regularly to detect leukopenia or anemia. - Renal function: assess serum creatinine and glomerular filtration rate periodically. - Liver enzymes: check hepatic function tests during treatment. - Live vaccines: avoid administration while on therapy due to infection risk. - Contraception: use effective birth control methods; drug may be teratogenic. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Mycophenolate Mofetil can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression may lead to severe cytopenias. - Antacids containing magnesium or aluminum: reduce oral absorption of mycophenolic acid. - Cyclosporine: increases mycophenolate exposure, raising toxicity risk. - Rifampin or other strong inducers: markedly decrease mycophenolate plasma levels. - Live vaccines: heightened risk of disseminated infection.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may exacerbate renal impairment when combined. - NSAIDs: increase risk of renal dysfunction and gastrointestinal irritation. - Vaccines (non‑live): monitor immune response effectiveness. - Cholesterol‑lowering agents (e.g., statins): watch for additive hepatic effects. - Hormonal contraceptives: possible reduced efficacy, advise backup method.